Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Core Insights - INOVIO announced the presentation of an abstract detailing the loss of detectable HPV-6 in patients with Recurrent Respiratory Papillomatosis after treatment with INO-3107 [1][2] - The abstract will be presented at the American Association for Cancer Research conference focused on immuno-oncology from February 23-26, 2025 [2] - INOVIO specializes in developing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases [3] Company Overview - INOVIO is a biotechnology company dedicated to the development and commercialization of DNA medicines [3] - The company's technology focuses on optimizing the design and delivery of innovative DNA medicines that enable the body to produce its own disease-fighting tools [3]